Compare AstraZeneca plc (AZN) vs The Coca-Cola Co K (KO) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Coca-Cola (KO) trades at $84.25, up 0.91% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.86 exceeding expectations. Revenue grew to $47.94B in 2025, with a robust net income margin of 27.8%. Analyst consensus is bullish with a $89.75 price target, and institutional buying activity is notable, supporting positive sentiment.

The outlook for KO remains favorable due to steady dividend growth, strong profitability, and global brand strength. Key risks include regional demand volatility and high debt levels. Investors may find value in its consistent earnings performance and analyst upside, though macroeconomic pressures could pose headwinds.